Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy F Olivieri

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Science and Engineering Ethics|March 21, 2003
Patients' health or company profits? The commercialisation of academic researchNancy F Olivieri
American Journal of Hematology|July 30, 2004
Adherence to deferoxamine therapy: heeding Hippocrates and OslerNancy F Olivieri
Blood Reviews|May 29, 2012
Treatment strategies for hemoglobin E beta-thalassemiaNancy F Olivieri
Nature|July 18, 2023
Industry: a poor record for whistle-blowersNancy F Olivieri, Morteza Mahmoudi
Cold Spring Harbor Perspectives in Medicine|June 5, 2013
Management of the thalassemiasNancy F Olivieri, Gary M Brittenham
The New England Journal of Medicine|February 28, 2019
The Role of Deferiprone in Iron ChelationBrenda L Gallie, Nancy F Olivieri
The Indian Journal of Medical Research|November 18, 2011
Hb E/beta-thalassaemia: a common & clinically diverse disorderNancy F Olivieri, Zahra Pakbaz, Elliott Vichinsky
Hematology/Oncology Clinics of North America|November 16, 2010
HbE/β-thalassemia: basis of marked clinical diversityNancy F Olivieri, Zahra Pakbaz, Elliott Vichinsky
Plos One|February 28, 2019
Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasiroxNancy F Olivieri, Amir Sabouhanian, Brenda L Gallie
Cancer Treatment and Research|November 30, 2022
Consequences to Patients, Clinicians, and Manufacturers When Very Serious Adverse Drug Reactions Are Identified (1997-2019): A Qualitative Analysis from the Southern Network on Adverse Reactions (SONAR)Courtney R Lubaczewski, Nancy F Olivieri, William R Hrushesky, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Science and Engineering Ethics|March 21, 2003
Patients' health or company profits? The commercialisation of academic researchNancy F Olivieri
American Journal of Hematology|July 30, 2004
Adherence to deferoxamine therapy: heeding Hippocrates and OslerNancy F Olivieri
Blood Reviews|May 29, 2012
Treatment strategies for hemoglobin E beta-thalassemiaNancy F Olivieri
Nature|July 18, 2023
Industry: a poor record for whistle-blowersNancy F Olivieri, Morteza Mahmoudi
Cold Spring Harbor Perspectives in Medicine|June 5, 2013
Management of the thalassemiasNancy F Olivieri, Gary M Brittenham
The New England Journal of Medicine|February 28, 2019
The Role of Deferiprone in Iron ChelationBrenda L Gallie, Nancy F Olivieri
The Indian Journal of Medical Research|November 18, 2011
Hb E/beta-thalassaemia: a common & clinically diverse disorderNancy F Olivieri, Zahra Pakbaz, Elliott Vichinsky
Hematology/Oncology Clinics of North America|November 16, 2010
HbE/β-thalassemia: basis of marked clinical diversityNancy F Olivieri, Zahra Pakbaz, Elliott Vichinsky
Plos One|February 28, 2019
Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasiroxNancy F Olivieri, Amir Sabouhanian, Brenda L Gallie
Cancer Treatment and Research|November 30, 2022
Consequences to Patients, Clinicians, and Manufacturers When Very Serious Adverse Drug Reactions Are Identified (1997-2019): A Qualitative Analysis from the Southern Network on Adverse Reactions (SONAR)Courtney R Lubaczewski, Nancy F Olivieri, William R Hrushesky, et al.
Pageof 4